Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New humira copycat tested in healthy chinese volunteers

NCT ID NCT07147257

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared a new biosimilar drug called CHS-1420 to the original Humira (adalimumab) in 238 healthy Chinese adults. Each person received a single injection of either CHS-1420 or Humira, and researchers measured how the drug moved through their blood over time. The goal was to see if the two drugs behave similarly in the body, which is a key step toward offering a more affordable treatment option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CHS-1420 (a proposed biosimilar of adalimumab)
What this could lead to
If successful, this could support approval of a more affordable version of Humira for inflammatory conditions.
What could go wrong
This is an early-phase trial in healthy people, not patients. It only checks drug levels in the blood, not actual treatment effects or safety in disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

238 people

The number who actually took part.

Started

Feb 2025

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Able to provide signed Informed Consent Form before the trial, and fully understand the trial content, process and possible adverse drug reactions (ADRs) 2. Able to complete the trial in compliance with the protocol 3. Participants (including males) willing to adopt effective contraceptive methods and with no pregnancy plan from 14 days before screening to 6 months after the last scheduled visit 4. Males and females between 18 and 55 years old, inclusive 5. At least 50 kg for participants, with a Body Mass Index(BMI)=Weight/ Height2 (kg/m2) between 19.0-26.0 kg/m2, inclusive 6. No history of chro nic or serious cardiac, hepatic, renal, digestive tract,nervous system, hematologic, respiratory, dermatological, mental and metabolic disorders, etc. Exclusion Criteria: 1. With ≥ 5 cigarettes per day on average within 3 months before screening, or not able to quit smoking during the trial 2. Allergic constitution, or allergic to the drug components and its analogues; history of allergic reaction to a biological medication 3. A history of alcohol abuse (alcohol consumption of more than 14 units per week : 1 unit of alcohol = 285 mL beer, or 25 mL spirits, or 100 mL wine) 4. Blood donation or massive blood loss (\> 400 mL) within 3 months before investigational products dosing; Or any blood donation plan from screening until 3 months after administration 5. History of any major surgery within the past year, or history of any surgery within the past 6 months; or any elective medical procedures, including dental procedures 6. Any history of organ transplantation 7. Medical history of tuberculosis (or suspected tuberculosis), or with a positive tuberculosis test result 8. Medical history of heart failure or other cardiac disorders which may lead to heart failure, e.g. coronary heart disease, hypertension, senile degenerative valvular disease, rheumatic valvular heart disease, dilated cardiomyopathy, acute severe myocarditis 9. Medical history of immune system disorders (e.g. systemic lupus erythematosus, multiple sclerosis, etc.), or positive results of antinuclear antibody tests 10. Medical history of recurrent or chronic infections (including transverse myelitis, optic neuritis, other demyelinating disorders, etc.), or a history of an opportunistic infection within the past year due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens 11. History of seizure attack 12. Medication history of TNF-α blockers e.g. Adalimumab or its analogues 13. Any medication of monoclonal antibodies within the past year before investigational products dosing 14. Any usage history of prescription medicines or OTCs (especially antibiotics), or Chinese herbal medicine or health supplementary within 30 days before investigational products dosing 15. Any vaccination within 3 months before investigational products dosing, or any plan for vaccination within 3 months after investigational products administration 16. Consumption of any special diets or food items (such as grapefruit), or strenuous exercise engagement, or other factors in the opinion of investigators affecting drug absorption, distribution, metabolism and excretion within 7 days before investigational products dosing 17. Participation in other drug clinical trials within 3 months before investigational products dosing 18. Any clinically significant abnormality findings, as judged by a clinical physican, such as physical examination, vital signs, electrocardiogram and laboratory tests, as well as Chest X-ray 19. Positive results of hepatitis B surface antigen, hepatitis C antibody, and HIV antibody or syphilis 20. Consumption of chocolate or any food/beverage containing caffeine or rich in xanthine within 48 h before investigational products dosing 21. Consumption of any products containing alcohol within 48 h before investigational products dosing, or a positive result of the alcohol breath test 22. A positive result of the drug abuse test, or a history of drug abuse in the past 5 years, or intake of any narcotic drugs within 3 months prior to the trial 23. A positive result of the pregnancy test, or in lactation during screening or the test period for female participants 24. Not tolerable on venipuncture, or a history of fainting on acupuncture and/or blood 25. Special requirements and unable to follow the unified diet 26. Unable to participate in this trial for participants' own reasons 27. Other conditions in which participants are not suitable for the trial determined by investigators

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy participants are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ethics Committee of Hopeshine-Minsheng Hospital of Xinzheng

    Zhengzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.